輝瑞稱已取消美塞拉競購中的部分條件

路透中文

11/06

<a href="https://laohu8.com/S/PFE">輝瑞</a>稱已取消美塞拉競購中的部分條件

路透特拉華州威明頓11月5日 - 輝瑞PFE.N週三在給特拉華州法官的一封信中說，輝瑞在競購美塞拉MTSR.O的過程中取消了一些條件，因為它試圖克服競爭對手諾和諾德NOVOb.CO對這家肥胖症藥物開發商的100億美元競購。

輝瑞將在週三舉行的聽證會上請求特拉華州法官阻止美特斯邦威終止雙方的合併協議，支持諾和諾德的出價。輝瑞表示，它取消了對美特斯邦威直接銷售股票和公開聲明的條件。

(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581037257"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581037257\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581037257?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-11-06 03:16","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581037257","market":"us","top_or_hot":-1,"title":"輝瑞稱已取消美塞拉競購中的部分條件","media":"路透中文","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PFE\">輝瑞</a>稱已取消美塞拉競購中的部分條件</title></head><body><p><span>路透特拉華州威明頓11月5日</span><span> - </span>輝瑞<span>PFE.N</span>週三在給特拉華州法官的一封信中說，輝瑞在競購美塞拉<span>MTSR.O</span>的過程中取消了一些條件，因為它試圖克服競爭對手<a href=\"https://laohu8.com/S/NVO\">諾和諾德</a><span>NOVOb.CO</span>對這家肥胖症藥物開發商的100億美元競購。</p><p>輝瑞將在週三舉行的聽證會上請求特拉華州法官阻止美特斯邦威終止雙方的合併協議，支持諾和諾德的出價。輝瑞表示，它取消了對美特斯邦威直接銷售股票和公開聲明的條件。</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>輝瑞稱已取消美塞拉競購中的部分條件</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n輝瑞稱已取消美塞拉競購中的部分條件\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1098195322\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">路透中文 </p>\n<p class=\"h-time smaller\">2025-11-06 03:16</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/PFE\">輝瑞</a>稱已取消美塞拉競購中的部分條件</title></head><body><p><span>路透特拉華州威明頓11月5日</span><span> - </span>輝瑞<span>PFE.N</span>週三在給特拉華州法官的一封信中說，輝瑞在競購美塞拉<span>MTSR.O</span>的過程中取消了一些條件，因為它試圖克服競爭對手<a href=\"https://laohu8.com/S/NVO\">諾和諾德</a><span>NOVOb.CO</span>對這家肥胖症藥物開發商的100億美元競購。</p><p>輝瑞將在週三舉行的聽證會上請求特拉華州法官阻止美特斯邦威終止雙方的合併協議，支持諾和諾德的出價。輝瑞表示，它取消了對美特斯邦威直接銷售股票和公開聲明的條件。</p><p>(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4599","symbol_name":"減肥藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL4S3WH1U5:1","article_id":"2581037257","we_media_id":"1098195322","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581037257","pubTimestamp":1762370217,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"路透中文","introduction":"路透中文","home_visible":1,"id":"1098195322","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"輝瑞稱已取消美塞拉競購中的部分條件路透特拉華州威明頓11月5日 - 輝瑞PFE.N週三在給特拉華州法官的一封信中説，輝瑞在競購美塞拉MTSR.O的過程中取消了一些條件，因為它試圖克服競爭對手諾和諾德NOVOb.CO對這家肥胖症藥物開發商的100億美元競購。輝瑞將在週三舉行的聽證會上請求特拉華州法官阻止美特斯邦威終止雙方的合併協議，支持諾和諾德的出價。輝瑞表示，它取消了對美特斯邦威直接銷售股票和公開聲明的條件。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4599":"减肥药","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","SG9999001176.USD":"United Global Healthcare Acc USD","BK4585":"ETF&股票定投概念","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","BK4534":"瑞士信贷持仓","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","SG9999002232.USD":"Allianz Global High Payout USD","PFE":"辉瑞","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","BK4592":"伊斯兰概念","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","BK4568":"美国抗疫概念","BK4550":"红杉资本持仓","BK4588":"碎股","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4007":"制药","MTSR":"Metsera Inc.","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0234572021.USD":"高盛美国核心股票组合Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","LU0122379950.USD":"贝莱德世界健康科学A2","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","BK4581":"高盛持仓"},"translate_title":"Pfizer says it has lifted some conditions in its Mercera bid","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PFE":0.9,"MTSR":0.9},"content_text":"輝瑞稱已取消美塞拉競購中的部分條件路透特拉華州威明頓11月5日 - 輝瑞PFE.N週三在給特拉華州法官的一封信中説，輝瑞在競購美塞拉MTSR.O的過程中取消了一些條件，因為它試圖克服競爭對手諾和諾德NOVOb.CO對這家肥胖症藥物開發商的100億美元競購。輝瑞將在週三舉行的聽證會上請求特拉華州法官阻止美特斯邦威終止雙方的合併協議，支持諾和諾德的出價。輝瑞表示，它取消了對美特斯邦威直接銷售股票和公開聲明的條件。(為便利非英文母語者，路透將其報導自動化翻譯為數種其他語言。由於自動化翻譯可能有誤，或未能包含所需語境，路透不保證自動化翻譯文本的準確性，僅是為了便利讀者而提供自動化翻譯。對於因為使用自動化翻譯功能而造成的任何損害或損失，路透不承擔任何責任。)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}